Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C

BACKGROUND: The aim of this study was to assess whether two-years treatment with Pirfenidone influences necroinflammation, fibrosis and steatosis, serum levels of TGF-β1, IL-6, TNF-α and CB1 and CB2 gene expression, in patients with chronic hepatitis C (CHC). METHODS: Twenty-eight patients out of 34...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Gastroenterol
Päätekijät: Flores-Contreras, Lucia, Sandoval-Rodríguez, Ana S, Mena-Enriquez, Mayra G, Lucano-Landeros, Silvia, Arellano-Olivera, Inmaculada, Álvarez-Álvarez, Arnulfo, Sanchez-Parada, M Guadalupe, Armendáriz-Borunda, Juan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2014
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4236537/
https://ncbi.nlm.nih.gov/pubmed/25064094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-230X-14-131
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia